Generate:Biomedicines announced a publication in Nature describing Chroma, a generative AI model that can program novel proteins not previously found in nature with targeted biophysical, biological, and therapeutic properties. Along with this announcement, the company is making the model available to the broader research community with the goal of accelerating...
Dose-escalation study to evaluate ORB-011 as single agent, with initial safety, pharmacokinetic and mechanism-based pharmacodynamic readouts
Orionis Biosciences, a life sciences company pioneering the creation of highly selective and tunable therapeutics for cancer and other diseases, announced that the first patient has been dosed in a Phase 1 clinical trial...
Charles River Laboratories International, Inc. and Aitia, a leader in the application of Causal AI and Digital Twins, announced a strategic agreement that gives Aitia access to Logica™, Charles River's Artificial Intelligence (AI) powered drug solution platform, for the optimized discovery and early development of multiple therapeutic programs for neurodegenerative disease and...
Code Ocean, the world's first Reproducible Research Cloud, announced that it has been selected as a winner of the 2023 BioTech Breakthrough Awards in the category of "QC Data Management Solution of the Year."
Code Ocean provides the first and only integrated library and workbench that guarantees reproducibility and speeds up...
VeriSIM Life announces recognition for continued advances with BIOiSIM, a first-in-class virtual drug development engine.
VeriSIM Life— the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development— announced that it has once again been named "Predictive Analytics Solution of the Year" at the 2023 BioTech Breakthrough Awards....
A global consortium of scientists from federal laboratories, research institutes, academia, and industry has formed to address the challenges of building large-scale artificial intelligence (AI) systems and advancing trustworthy and reliable AI for scientific discovery.
The Trillion Parameter Consortium (TPC) brings together teams of researchers engaged in creating large-scale generative AI models to address...
Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, announced that they have updated the focus of their research collaboration to precision oncology.
The oncology-focused collaboration will leverage Bayer’s small molecule compound library and expertise in biology and medicinal chemistry as well...
Certis Oncology Solutions (Certis), a translational science and precision oncology company, announced it has been selected as "Overall Immunology Company of the Year" in the third annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and...
Investment supported by additional financing from a strong syndicate of new and existing institutional investors, along with industry leaders
Terray Therapeutics, a biotechnology company integrating scale experimentation and generative AI to improve the speed, cost, and success rate of small molecule drug discovery and development, announced an equity investment by...
Osmo, a machine olfaction startup, announced the receipt of a $3.5 million grant from the Bill & Melinda Gates Foundation to advance the company's AI-enabled scent platform for discovering and producing compounds that repel, attract, or destroy disease-carrying insects to improve animal and human health. The grant is in addition to...
